

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 September 2021 (30.09.2021)



(10) International Publication Number
WO 2021/195553 A1

(51) International Patent Classification:

A61K 38/00 (2006.01) C07K 7/08 (2006.01)
A61K 38/10 (2006.01) C07K 14/00 (2006.01)
A61K 38/16 (2006.01) C07K 14/72 (2006.01)
A61P 35/00 (2006.01) C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2021/024467

(22) International Filing Date:

26 March 2021 (26.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/000,322 26 March 2020 (26.03.2020) US

(71) Applicant: **ESPERANCE PHARMACEUTICALS, INC**
[US/US]; 909 FANNIN ST., SUITE 2000, HOUSTON,
Texas 77010 (US).

(72) Inventors: **LEUSCHNER, Carola**; 5 Rutgers Place, Hous-
ton, Texas 77005 (US). **ALILA, Hector**; 1506 Dan Cox
Avenue, Katy, Texas 77493 (US). **SOOD, Anil**; 2719 Lake-

crest Drive, Pearland, Texas 77584 (US). **KIM, Mark**;
3710 Main Poplar Drive, Houston, Texas 77025 (US).


(74) Agent: **ROBINSON, Carmen K.**; c/o PILLSBURY WIN-
THROP SHAW PITTMAN LLP, P.O. BOX 10500,
McLean, Virginia 22101 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: LYTIC DOMAIN FUSION CONSTRUCTS, CHECKPOINT INHIBITORS, AND METHODS OF MAKING AND USING
SAME

Fig. 17B



(57) Abstract: The invention relates to fusion constructs and checkpoint inhibitors, methods of using fusion constructs and checkpoint inhibitors, and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*